Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1453-1460

  Parmentier Batteur, Sophie ^a   Obrien, Julie A ^a   Doran, Scott ^a   Nguyen, Shannon J ^a   Flick, Rosemarie Beth ^a   Uslaner, Jason M ^a   Chen, Hank ^a   Finger, Eleftheria N ^a   Williams, Theresa M ^a   Jacobson, Marlene A ^a   Hutson, Pete H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antipsychotic activity; CDPPB; mGlu5 receptor; NMDA receptor subunit phosphorylation; Receptor binding; Sleep

Indexed keywords

3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPSYCHOTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FRONTAL CORTEX; INTERMETHOD COMPARISON; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PSYCHOMOTOR ACTIVITY; RAT; WESTERN BLOTTING;

ALLOSTERIC REGULATION; ANIMALS; BENZAMIDES; CEREBRAL CORTEX; CORPUS STRIATUM; MALE; PSYCHOMOTOR AGITATION; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; SLEEP;

EID: 84856091327     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.11.013     Document Type: Article

References (50)

1. M. Armstrong-James, and K. Fox Evidence for a specific role for cortical NMDA receptors in slow-wave sleep Brain Res. 451 1988 189 196
2. J. Arnt, T. Skarsfeldt, and J. Hyttel Differentiation of classical and novel antipsychotics using animal models Int. Clin. Psychopharmacol. 12 Suppl. 1 1997 S9 17
3. E. Aronica, F. Nicoletti, D.F. Condorelli, and R. Balazs Pharmacological characterization of metabotropic glutamate receptors in cultured cerebellar granule cells Neurochem. Res. 18 1993 605 612 (Pubitemid 23118936)
4. S. Attucci, V. Carla, G. Mannaioni, and F. Moroni Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges Br. J. Pharmacol. 132 2001 799 806 (Pubitemid 32193636)
5. H. Awad, G.W. Hubert, Y. Smith, A.I. Levey, and P.J. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
6. D. Balschun, W. Zuschratter, and W. Wetzel Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory Neuroscience 142 2006 691 702 (Pubitemid 44485913)
7. M.H. Chan, P.H. Chiu, J.H. Sou, and H.H. Chen Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice Psychopharmacology (Berl) 198 2008 141 148
8. N.D. Cosford, J. Roppe, L. Tehrani, E.J. Schweiger, T.J. Seiders, A. Chaudary, S. Rao, and M.A. Varney [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor Bioorg. Med. Chem. Lett. 13 2003 351 354 (Pubitemid 36259690)
9. J.M. Darrah, M.R. Stefani, and B. Moghaddam Interaction of N-methyl-d-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm Behav. Pharmacol. 19 2008 225 234 (Pubitemid 351670403)
10. V. de Novellis, D. Siniscalco, U. Galderisi, C. Fuccio, M. Nolano, L. Santoro, A. Cascino, K.A. Roth, F. Rossi, and S. Maione Blockade of glutamate mGlu5 receptors in a rat model of neuropathic pain prevents early over-expression of pro-apoptotic genes and morphological changes in dorsal horn lamina II Neuropharmacology 46 2004 468 479 (Pubitemid 38224432)
11. A.J. Doherty, M.J. Palmer, J.M. Henley, G.L. Collingridge, and D.E. Jane (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus Neuropharmacology 36 1997 265 267 (Pubitemid 27149516)
12. A.J. Doherty, M.J. Palmer, Z.A. Bortolotto, A. Hargreaves, A.E. Kingston, P.L. Ornstein, D.D. Schoepp, D. Lodge, and G.L. Collingridge A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices Br. J. Pharmacol. 131 2000 239 244
13. I. Feinberg, and I.G. Campbell Ketamine administration during waking increases delta EEG intensity in rat sleep Neuropsychopharmacology 9 1993 41 48 (Pubitemid 23242599)
14. F. Fumagalli, A. Frasca, G. Racagni, and M.A. Riva Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs Mol. Pharmacol. 73 2008 1484 1490 (Pubitemid 351574838)
15. K. Fuxe, D. Marcellino, A. Rivera, Z. Diaz-Cabiale, M. Filip, B. Gago, D.C. Roberts, U. Langel, S. Genedani, L. Ferraro, A. de la Calle, J. Narvaez, S. Tanganelli, A. Woods, and L.F. Agnati Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology Brain Res. Rev. 58 2008 415 452
16. R.W.T. Gereau, and S.F. Heinemann Role of protein kinase C phosphorylation in rapid desensitization of metabotropic glutamate receptor 5 Neuron 20 1998 143 151 (Pubitemid 28078357)
17. A. Gravius, A. Dekundy, J. Nagel, L. More, M. Pietraszek, and W. Danysz Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats J. Neural. Trans. 115 2008 1609 1619
18. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, A. Horowitz, and D. Kelly Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia Br. J. Psychiatry 169 1996 610 617
19. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch. Gen. Psychiatry 56 1999 29 36 (Pubitemid 29055047)
20. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am. J. Psychiatry 159 2002 480 482 (Pubitemid 34184748)
21. H. Homayoun, and B. Moghaddam Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs Proc. Natl. Acad. Sci. U.S.A. 105 2008 18041 18046
22. D.C. Javitt Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia Hillside J. Clin. Psychiatry 1987 12 35
23. G. Juhasz, K. Kekesi, Z. Emri, I. Soltesz, and V. Crunelli Sleep-promoting action of excitatory amino acid antagonists: a different role for thalamic NMDA and non-NMDA receptors Neurosci. Lett. 114 1990 333 338 (Pubitemid 20205158)
24. J.A. Kerner, D.G. Standaert, J.B. Penney Jr.; A.B. Young, and G.B. Landwehrmeyer Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus Brain Res. Mol. Brain Res. 48 1997 259 269 (Pubitemid 27390062)
25. G.G. Kinney, M. Burno, U.C. Campbell, L.M. Hernandez, D. Rodriguez, L.J. Bristow, and P.J. Conn Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents J. Pharmacol. Exp. Ther. 306 2003 116 123 (Pubitemid 36734364)
26. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 313 2005 199 206 (Pubitemid 40411343)
27. A. Klodzinska, E. Tatarczynska, E. Chojnacka-Wojcik, G. Nowak, N.D. Cosford, and A. Pilc Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling Neuropharmacology 47 2004 342 350 (Pubitemid 38953225)
28. S.A. Kotecha, and J.F. MacDonald Signaling molecules and receptor transduction cascades that regulate NMDA receptor-mediated synaptic transmission Int. Rev. Neurobiol. 54 2003 51 106
29. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
30. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467 (Pubitemid 32830950)
31. J.Y. Lan, V.A. Skeberdis, T. Jover, X. Zheng, M.V. Bennett, and R.S. Zukin Activation of metabotropic glutamate receptor 1 accelerates NMDA receptor trafficking J. Neurosci. 21 2001 6058 6068 (Pubitemid 32737739)
32. F. Liu, G. Zhang, G. Hornby, D. Vasylyev, M. Bowlby, K. Park, A. Gilbert, K. Marquis, and T.H. Andree The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices Eur. J. Pharmacol. 536 2006 262 268
33. F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P.J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, D. Smith, M. Olsen, E. Kouranova, M. Lai, F. Pruthi, C. Pulicicchio, M. Day, A. Gilbert, M.H. Pausch, N.J. Brandon, C.E. Beyer, T.A. Comery, S. Logue, S. Rosenzweig-Lipson, and K.L. Marquis ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol- 5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 327 2008 827 839
34. G. Mannaioni, M.J. Marino, O. Valenti, S.F. Traynelis, and P.J. Conn Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function J. Neurosci. 21 2001 5925 5934 (Pubitemid 32737725)
35. A.M. Milasius, K.K. Grinevicius, and I.P. Lapin Effect of quinolinic acid on wakefulness and sleep in the rabbit J. Neural. Trans. Gen. Sect. 82 1990 67 73 (Pubitemid 20234495)
36. R.E. Nordquist, S. Durkin, G. Jaeschke, and W. Spooren Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP Eur. J. Pharmacol. 568 2007 199 202 (Pubitemid 46976909)
37. S. Patel, T.G. Hamill, B. Connolly, E. Jagoda, W. Li, and R.E. Gibson Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB Nucl. Med. Biol. 34 2007 1009 1017 (Pubitemid 350061172)
38. A.J. Pijnenburg, W.M. Honig, and J.M. Van Rossum Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat Psychopharmacologia 41 1975 87 95
39. A. Pilc, A. Klodzinska, P. Branski, G. Nowak, A. Palucha, B. Szewczyk, E. Tatarczynska, E. Chojnacka-Wojcik, and J.M. Wieronska Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats Neuropharmacology 43 2002 181 187 (Pubitemid 35247606)
40. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587 (Pubitemid 32925246)
41. P. Popoli, A. Pezzola, M. Torvinen, R. Reggio, A. Pintor, L. Scarchilli, K. Fuxe, and S. Ferre The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors Neuropsychopharmacology 25 2001 505 513 (Pubitemid 32830955)
42. F.M. Ribeiro, L.T. Ferreira, M. Paquet, T. Cregan, Q. Ding, R. Gros, and S.S. Ferguson Phosphorylation-independent regulation of metabotropic glutamate receptor 5 desensitization and internalization by G protein-coupled receptor kinase 2 in neurons J. Biol. Chem. 284 2009 23444 23453
43. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia Pharmacol. Biochem. Behav. 95 2009 23 30
44. N. Sevostianova, and W. Danysz Analgesic effects of mGlu1 and mGlu5 receptor antagonists in the rat formalin test Neuropharmacology 51 2006 623 630 (Pubitemid 44215967)
45. S.J. Tallaksen-Greene, K.W. Kaatz, C. Romano, and R.L. Albin Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons Brain Res. 780 1998 210 217 (Pubitemid 28082908)
46. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle d-serine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 44 1998 1081 1089 (Pubitemid 28547143)
47. S.J. Tsai, C.Y. Cheng, C.J. Hong, D.L. Liao, and Y.J. Liou Polymorphisms in glycine transporter with schizophrenia Neuropsychopharmacol. Hung. 8 2006 17 21
48. A. Ugolini, M. Corsi, and F. Bordi Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons Neuropharmacology 38 1999 1569 1576 (Pubitemid 29457738)
49. J.M. Uslaner, S. Parmentier-Batteur, R.B. Flick, N.O. Surles, J.S. Lam, C.H. McNaughton, M.A. Jacobson, and P.H. Hutson Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus Neuropharmacology 57 2009 531 538
50. J.D. Vardigan, S.L. Huszar, C.H. McNaughton, P.H. Hutson, and J.M. Uslaner MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol. Biochem. Behav 95 2010 223 229